EPHX2 and coronary artery disorder: It is reported that CYP-mediated eicosanoid metabolism is dysregulated in certain subsets of CHD patients, and demonstrate that biomarkers of CYP epoxygenase and soluble epoxide hydrolase, but not CYP-hydroxylase, metabolism are altered in stable CHD patients relative to healthy individuals [75].